NCT07230106 2026-03-03
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
Clinical Trials
36 trialsNCT07424287 2026-02-20
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Not yet recruiting
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT07192120 2025-09-25
A Study of MHB048C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT04186845 2025-09-22
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics
Phase 3 Completed
NCT06241846 2025-08-27
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2 Recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT06754085 2024-12-31
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
HTA Co., Ltd.
Phase 3 Recruiting
NCT06683066 2024-11-12
Study on Human Bioequivalence of Triprerelin Acetate for Injection
The Affiliated Hospital of Qingdao University
Phase 1 Recruiting
NCT06592326 2024-09-19
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06378242 2024-07-11
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT06387056 2024-04-26
SEGNO
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06301308 2024-04-24
A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Second Xiangya Hospital of Central South University
Phase 3 Withdrawn
NCT04028388 2024-04-17
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Phase 2 Completed
NCT06282588 2024-02-28
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT06022757 2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT04073602 2023-12-18
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT03809013 2023-11-27
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT05140512 2023-05-16
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 1 Completed
NCT05856630 2023-05-12
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Luye Pharma Group Ltd.
Phase 1 Unknown
NCT03709550 2022-10-05
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT05488353 2022-08-04
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4 Not yet recruiting
NCT04563936 2021-08-26
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 3 Completed
NCT04568304 2020-09-29
A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Unknown
NCT04272645 2020-07-15
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02647983 2020-01-22
Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection
Sunnybrook Health Sciences Centre
Phase 1 Withdrawn
NCT03507166 2019-08-21
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT02584400 2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2 Terminated
NCT01993160 2017-01-13
18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer
University Health Network, Toronto
Phase NA Completed
NCT01481441 2016-07-06
AMC_2011_190
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Terminated
NCT00667537 2015-12-14
PK in Pts With HRPC & Skeletal Metastes
Bayer
Phase 1 Completed
NCT01229618 2015-10-05
Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT02208583 2014-08-05
Molecular Phenotype Changes and Personalized Treatment for CRPC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT00918281 2014-06-09
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Phase 2 Completed